Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells
Mariella D'Alessandro1, Stephanie E Coats, Marcel F Jonkman
1CR UK Cell Structure Research Group, Division of Molecular Medicine, College of Life Sciences, University of Dundee, Dundee, UK. m.dalessandro@dundee.ac.uk
Abstract:
Skin fragility disorders caused by keratin mutations are incurable, and a better understanding of their etiology is needed to find new ways to improve and treat these conditions. The best-studied skin fragility disorder is epidermolysis bullosa simplex (EBS), an autosomal dominant condition caused by mutations in keratin 5 (K5) or K14. To analyze disease mechanisms and develop gene therapy strategies, we have used keratinocyte cell lines derived from EBS patients as model systems. Here, we describe two cell lines established from EBS patients with K14-null mutations. We analyze the responses of these cells to stress assays previously shown to discriminate between wild-type and keratin-mutant keratinocytes, to directly evaluate the efficacy of rescuing K14-null cells by supplementation with wild-type K14 complementary DNA (cDNA). The K14-null cells show elevated levels of stress correlating with reduced normal keratin function. By transfecting wild-type K14 into these cells, we demonstrate "proof of principle" that an add-back approach can significantly rescue the normal keratinocyte behavior profile. These K14-null cell lines provide a disease model for studying the effects of keratin ablation in EBS patients and to test the efficacy of gene add-back and other therapy approaches in keratinocytes.
Insights
Researchers developed a new cell model for epidermolysis bullosa simplex (EBS) by creating keratin 14-null cells. Gene add-back therapy successfully restored normal keratinocyte function, offering hope for treating this incurable skin fragility disorder.
Area of Science:
- Cell Biology
- Genetics
- Dermatology
Background:
- Skin fragility disorders, such as epidermolysis bullosa simplex (EBS), stem from keratin gene mutations and currently lack cures.
- Mutations in keratin 5 (K5) or keratin 14 (K14) genes are primary causes of EBS, a well-studied condition.
- Understanding the molecular mechanisms of EBS is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To establish and characterize keratinocyte cell lines from EBS patients with K14-null mutations.
- To evaluate the functional consequences of K14 deficiency in these cell lines using stress assays.
- To demonstrate the potential of gene add-back therapy for rescuing keratinocyte function in EBS models.
Main Methods:
- Generation of two keratinocyte cell lines from EBS patients lacking functional K14.
- Application of stress assays to compare K14-null cells with wild-type keratinocytes.
- Transfection of wild-type K14 complementary DNA (cDNA) into K14-null cells to assess rescue efficacy.
Main Results:
- K14-null keratinocytes exhibited heightened stress responses, indicating impaired keratin function.
- Supplementation with wild-type K14 cDNA significantly restored normal keratinocyte behavior.
- The study provides proof of principle for gene add-back as a viable therapeutic approach.
Conclusions:
- The developed K14-null cell lines serve as a valuable disease model for studying keratin ablation in EBS.
- Gene add-back therapy demonstrates significant potential for rescuing cellular phenotypes in EBS keratinocytes.
- These findings pave the way for further investigation into gene therapy strategies for incurable skin fragility disorders.
